2026 MaTOS GU | Session X | Prostate, Penile and Testicular Cancers
Overview
Dr. Lawal: PSMA therapy shows strong PSA responses; actinium may overcome resistance; future focus on dosing, combos, and reducing toxicity.
Dr. Madan: bispecific T-cell engagers (STEAP1, KLK2, PSMA) show PSA responses with manageable CRS; cytokines key to boosting immunotherapy efficacy.
Dr. Khan: neuroendocrine prostate cancer is rare, aggressive; chemo mainstay, IO under study; DLL3-targeted and T-cell therapies show emerging promise.
Dr. Sonpavde: penile cancer—TIP is preferred (50% ORR); platinum+IO used; EGFR, HER2, TROP2 targets and InPACT trial under study.
Dr. Adra: testicular cancer updates—miR-371 predicts relapse, RPLND may avoid chemo, new targets emerging; survivorship highlights long-term chemo effects.
Panel: PSMA PET has limits—heterogeneous expression, SUV mean useful but hard to use; tumor volume not predictive; need better biomarkers and research.
Dr. Madan: bispecific T-cell engagers (STEAP1, KLK2, PSMA) show PSA responses with manageable CRS; cytokines key to boosting immunotherapy efficacy.
Dr. Khan: neuroendocrine prostate cancer is rare, aggressive; chemo mainstay, IO under study; DLL3-targeted and T-cell therapies show emerging promise.
Dr. Sonpavde: penile cancer—TIP is preferred (50% ORR); platinum+IO used; EGFR, HER2, TROP2 targets and InPACT trial under study.
Dr. Adra: testicular cancer updates—miR-371 predicts relapse, RPLND may avoid chemo, new targets emerging; survivorship highlights long-term chemo effects.
Panel: PSMA PET has limits—heterogeneous expression, SUV mean useful but hard to use; tumor volume not predictive; need better biomarkers and research.
Target Audience
Physicians
This material is non‑CME, no credits are available, and a certificate will not be provided upon completion.
Faculty
Speakers and Panelists:
Ismaheel O. Lawal, MD, PhD
Ravi A. Madan, MD
Hiba Khan, MD, MPH
Guru Sonpavde, MD
Nabil Adra, MD, MS
Date of Release
February 11th, 2026
%2016.47.03-1770752981975.webp&w=3840&q=75)
